Catalog No.
RHJ91701
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400
Target
Osteoclast differentiation factor receptor, Receptor activator of NF-KB, TNFRSF11A, ODFR, Tumor necrosis factor receptor superfamily member 11A, CD265, RANK
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9Y6Q6
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3X84
RANK/RANKL Signaling Pathway in Breast Development and Cancer., PMID:39821032
Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals., PMID:37373436
ADR3, a next generation i-body to human RANKL, inhibits osteoclast formation and bone resorption., PMID:36634847
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial., PMID:36535121
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer., PMID:33785053
Human apoptosis antibody array-membranes studying the apoptotic effect of marine bacterial exopolysaccharides in HepG2 cells., PMID:33723130
The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer., PMID:33119864
Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia., PMID:33075129
Histone H3.3 mutation in giant cell tumor of bone: an update in pathology., PMID:31748824
Expression Profiling of Receptor-Activator of Nuclear Factor-Kappa B Ligand in Soft Tissue Tumors., PMID:31189751
Expression of the RANK/RANKL/OPG system in the human intervertebral disc: implication for the pathogenesis of intervertebral disc degeneration., PMID:31101043
The RANKL-RANK Axis: A Bone to Thymus Round Trip., PMID:30984193
Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells., PMID:30947287
RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment., PMID:30661662
Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden., PMID:30496606
Dynamics of Bone Cell Interactions and Differential Responses to PTH and Antibody-Based Therapies., PMID:30460589
Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy., PMID:30232468
[Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them?]., PMID:29871576
Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system., PMID:29702364
Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line., PMID:29557068
Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway., PMID:29074954
The Cell Surface Markers Expression in Postmenopausal Women and Relation to Obesity and Bone Status., PMID:28696349
BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells., PMID:28388533
Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment., PMID:28283537
Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases., PMID:28185765
RANKL/RANK: from bone loss to the prevention of breast cancer., PMID:27881737
Interleukin-4 released from human gingival fibroblasts reduces osteoclastogenesis., PMID:27608363
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers., PMID:27322743
Characterization and application of two RANK-specific antibodies with different biological activities., PMID:26773232
Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts., PMID:26659358
RANKL/RANK interaction promotes the growth of cervical cancer cells by strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion., PMID:26398902
Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series., PMID:26338802
Denosumab for the treatment of giant cell tumor of the bone., PMID:26161925
Improved efficacy of soluble human receptor activator of nuclear factor kappa B (RANK) fusion protein by site-directed mutagenesis., PMID:25974308
Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts., PMID:25956608
Outflanking RANK with a designer antagonist cytokine., PMID:25140052
Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL., PMID:25138051
RANK expression as a prognostic and predictive marker in breast cancer., PMID:24737168
Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways., PMID:24676805
A novel therapeutic strategy for adolescent idiopathic scoliosis based on osteoporotic concept., PMID:23562283
[Paget's disease of bone: new therapeutic strategies]., PMID:23548950
Targeting RANKL in breast cancer: bone metastasis and beyond., PMID:23406560
[RANKL inhibition in bone metastases]., PMID:23302944
Immunoexpression of RANK, RANKL, OPG, VEGF, and vWF in radicular and dentigerous cysts., PMID:23278112
Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition., PMID:23246105
Psoriatic arthritis: treatment strategies using biologic agents., PMID:22690388
Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss., PMID:21844205
[Involvement of RANKL/RANK pathway in bone metastasis in breast cancer]., PMID:21814020
[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis]., PMID:21052563
Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin., PMID:19812402
For research use only. Not for human or drug use.
